PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells

References

• XuWChenQWangQJWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cellsCell Death Dis2014512e155125476899
   PubMedGoogle Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• CatalanoVLabiancaRBerettaGDGattaGde BraudFvan CutsemEGastric cancerCrit Rev Oncol Hematol200971212716419230702
   PubMed Web of Science ®Google Scholar
• ChabnerBARobertsTGTimeline: chemotherapy and the war on cancerNat Rev Cancer200551657215630416
   PubMed Web of Science ®Google Scholar
• KimBLeeKWKimMJA multicenter randomized Phase II study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after Cisplatin Plus Either S-1 or CapecitabineEur J Cancer2017493706716
   Google Scholar
• BangYJvan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKvan CutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• ChoKWangXNieSChenZGShinDMTherapeutic nanoparticles for drug delivery in cancerClin Cancer Res20081451310131618316549
   PubMed Web of Science ®Google Scholar
• FengS-SZhaoLZhangZChemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivoChem Eng Sci2007622366416648
   Web of Science ®Google Scholar
• WangXYangLChenZGShinDMApplication of nanotechnology in cancer therapy and imagingCA Cancer J Clin20085829711018227410
   PubMed Web of Science ®Google Scholar
• YooHSParkTGFolate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugateJ Control Release2004100224725615544872
   PubMed Web of Science ®Google Scholar
• BrownKCPeptidic tumor targeting agents: the road from phage display peptide selections to clinical applicationsCurr Pharm Des20101691040105420030617
   PubMed Web of Science ®Google Scholar
• AdamsGPWeinerLMMonoclonal antibody therapy of cancerNat Biotechnol20052391147115716151408
   PubMed Web of Science ®Google Scholar
• AhlgrenSWållbergHTranTATargeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteineJ Nucl Med200950578178919372467
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• TopalianSLDrakeCGPardollDMTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurr Opin Immunol201224220721222236695
   PubMed Web of Science ®Google Scholar
• DasSSuarezGBeswickEJSierraJCGrahamDYReyesVEExpression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylor infectionJ Immunol200617653000300916493058
   PubMedGoogle Scholar
• KimJWNamKHAhnSHPrognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancerGastric Cancer2016191425225424150
   PubMed Web of Science ®Google Scholar
• QingYLiQRenTUpregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancerDrug Des Devel Ther20159901909
   PubMed Web of Science ®Google Scholar
• WuCZhuYJiangJZhaoJZhangXGXuNImmunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significanceActa Histochem20061081192416530813
   PubMed Web of Science ®Google Scholar
• HouJYuZXiangRCorrelation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancerExp Mol Pathol201496328429124657498
   PubMed Web of Science ®Google Scholar
• GengYWangHLuCExpression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significanceInt J Clin Oncol201520227328124804867
   PubMed Web of Science ®Google Scholar
• NishiyamaNKataokaKCurrent state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene deliveryPharmacol Ther2006112363064816815554
   PubMed Web of Science ®Google Scholar
• LiRLiXXieLPreparation and evaluation of PEG-PCL nanoparticles for local tetradrine deliveryInt J Pharm2009379115816619524653
   PubMed Web of Science ®Google Scholar
• LiuYLiKLiuBFengSSA strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug deliveryBiomaterials201031359145915520864169
   PubMed Web of Science ®Google Scholar
• WangYGaoSYeWHYoonHSYangYYCo-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymerNat Mater200651079179616998471
   PubMed Web of Science ®Google Scholar
• ZhangDZouZRenWGambogic acid-loaded PEG-PCL nanoparticles act as an effective antitumor agent against gastric cancerPharm Dev Technol2018231334029069711
   PubMed Web of Science ®Google Scholar
• JungJParkSJChungHKPolymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancerInt J Radiat Oncol Biol Phys2012841e77e8322795728
   PubMed Web of Science ®Google Scholar
• EinzigAINeubergDRemickSCPhase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293Med Oncol199613287939013471
   PubMedGoogle Scholar
• Thuss-PatiencePCKretzschmarAReppMDocetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II studyJ Clin Oncol200523349450115659494
   PubMedGoogle Scholar
• SharmaPAllisonJPThe future of immune checkpoint therapyScience20153486230566125838373
   PubMed Web of Science ®Google Scholar
• GongWSongQLuXPaclitaxel induced B7-H1 expression in cancer cells via the MAPK pathwayJ Chemother201123529529922005063
   PubMed Web of Science ®Google Scholar
• PatelSPKurzrockRPD-L1 expression as a predictive biomarker in Cancer immunotherapyMol Cancer Ther201514484785625695955
   PubMed Web of Science ®Google Scholar
• LiangSCLatchmanYEBuhlmannJERegulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responsesEur J Immunol200333102706271614515254
   PubMed Web of Science ®Google Scholar
• WangAZLangerRFarokhzadOCNanoparticle delivery of cancer drugsAnnu Rev Med2012636318519821888516
   PubMedGoogle Scholar
• FriedmanADClaypoolSELiuRThe smart targeting of nanoparticlesCurr Pharm Des201319356315632923470005
   PubMed Web of Science ®Google Scholar
• WhiteheadKALangerRAndersonDGKnocking down barriers: advances in siRNA deliveryNat Rev Drug Discov20098212913819180106
   PubMed Web of Science ®Google Scholar
• RamakrishnanRAssudaniDNagarajSChemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in miceJ Clin Invest201012041111112420234093
   PubMed Web of Science ®Google Scholar
• van der MostRGCurrieAJCleaverALCyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthPLoS One200949e698219746156
   PubMed Web of Science ®Google Scholar
• GalluzziLBuquéAKeppOZitvogelLKroemerGImmunological effects of conventional chemotherapy and targeted anticancer agentsCancer Cell201528669071426678337
   PubMed Web of Science ®Google Scholar
• MénardCMartinFApetohLBouyerFGhiringhelliFCancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunityCancer Immunol Immunother200857111579158718369619
   PubMed Web of Science ®Google Scholar
• GadgeelSStevensonJLangerCJPembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-CJ Clin Oncol2016suppl 1590169016
   Google Scholar
• MartinoECMissoGPastinaPImmune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patientsCell Death Discov201621602527752361
   PubMed Web of Science ®Google Scholar
• AtzpodienJKirchnerHJonasUInterleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German cooperative renal carcinoma chemoimmunotherapy group (DGCIN)J Clin Oncol20042271188119414981107
   PubMedGoogle Scholar
• ParraHSTixiLLatteriFCombined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)Cancer200192365065611505411
   PubMedGoogle Scholar